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Abstract Immunity induced by DNA vaccines contain-
ing the hemagglutinin (H) and nucleoprotein (N) genes of
wild-type and attenuated canine distemper virus (CDV)
was investigated in mink (Mustela vison), a highly sus-
ceptible natural host of CDV. All DNA-immunized mink
seroconverted, and significant levels of virus-neutralizing
(VN) antibodies were present on the day of challenge with
wild-type CDV. The DNA vaccines also primed the cell-
mediated memory responses, as indicated by an early
increase in the number of interferon-gamma (IFN-c)-pro-
ducing lymphocytes after challenge. Importantly, the wild-
type and attenuated CDV DNA vaccines had a long-term
protective effect against wild-type CDV challenge. The
vaccine-induced immunity induced by the H and N genes
from wild-type CDV and those from attenuated CDV was
comparable. Because these two DNA vaccines were shown
to protect equally well against wild-type virus challenge, it
is suggested that the genetic/antigenic heterogeneity
between vaccine strains and contemporary wild-type
strains are unlikely to cause vaccine failure.
Introduction
Canine distemper virus (CDV) is a member of the genus
Morbillivirus, family Paramyxoviridae, that is closely
related to measles virus (MeV), which infects humans [1].
These highly virulent contagious viruses cause severe
diseases in their respective hosts worldwide, illustrating the
need for the development of more efficacious and safer
vaccines.
The lymphotropic CDV can cause a systemic, poten-
tially fatal disease associated with severe immunosup-
pression in a broad range of domestic and wild carnivores
including dog, mink and ferrets [2, 3]. Despite the use of
attenuated live vaccines, outbreaks of distemper in both
vaccinated and unvaccinated individuals have been repor-
ted [4–14].
The hemagglutinin (H) protein is the key determinant in
viral entry, as it mediates the binding of the virus to the
signalling lymphocyte activation molecule receptor
(SLAM/CD150) at the surface of susceptible cells and
thereby initiates virus infection [15, 16]. A possible reason
for vaccine failure may be variation between the H proteins
of the CDV strains used in vaccines and those of the cur-
rently circulating wild-type strains [9, 10, 17–19].
CDV strains worldwide can be divided into distinct
geographically separated subtypes based on the H gene,
namely, America-1, America-2, European, Arctic, Asia-1
and Asia-2 [17, 19–23]. The current and widely used CDV
vaccines (such as Onderstepoort and Snyder Hill) are based
on different attenuated strains isolated before 1960 and
belong to the America-1 group [15]. It is uncertain whether
the America-1 CDV strains still are circulating in the field,
since they have not been seen in the last five decades [24].
The greatest diversity both genetically and antigenically is
seen between field CDV isolates and the traditional vaccine
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strains [10, 25–27]. The marked genetic and antigenic
variation between wild-type CDV and vaccine CDV strains
has been suggested to play a role in vaccine failures in
animals immunized with attenuated live vaccine against
circulating wild-type CDV [10, 19, 25, 27, 28]. Therefore,
it is of high relevance to study the protective effects of
DNA vaccines against wild-type CDV.
DNA vaccines have several advantages over attenuated
live vaccines: (1) they contain no infectious components,
while serious or even fatal infections can occur subsequent
to vaccination with live CDV vaccines in some wildlife
species [29–32], (2) they stimulate both long-lasting cellular
and humoral immune response without any risk of reversion
to virulence [33], and (3) they have the ability to induce
immunity against morbilliviruses in offspring in the pres-
ence of maternal immunity [34–37]. A disadvantage of
plasmid-DNA-based vaccines is the inefficient uptake of
plasmid by cells because of inefficient delivery. This inef-
ficient uptake results in less antigen production and the
humoral immune response is thus limited. The first study of
DNA vaccination in a natural host of CDV showed that dogs
immunized with plasmids encoding the H, nucleoprotein
(N) and fusion (F) genes were protected against severe
clinical disease, while only a limited humoral response was
induced [38]. The humoral response induces mainly virus-
neutralizing (VN) antibodies directed against the H protein.
A minor fraction of the VN antibodies are directed against
the F protein, and these probably prevent fusion between the
viral envelope and the host-cell membrane [39–43].
In earlier studies, it was demonstrated that vaccination
with DNA vaccines consisting of the H and N genes from
the attenuated CDV Onderstepoort strain conferred solid
cross-protection against infection of mink with virulent
wild-type CDV strains [44–46]. The studies showed that the
vaccine-specific VN antibody and cell-mediated responses
that were induced provided robust protection against dis-
ease development in both adult and young mink [44–46].
In the present study, a new DNA vaccine, containing
plasmids encoding the H, N and F genes from wild-type
CDV derived from a distemper outbreak in partly vacci-
nated dogs in Denmark in 1991 (DK91) [5], was devel-
oped. A possible explanation for vaccine failure found
during the Danish distemper outbreak could be interference
by maternally-derived antibodies [5]. Another explanation
could be inappropriate vaccination due to immunization
immediately before or after viral exposure.
In this study, the immunogenicity of a novel wild-type
DNA vaccine and a DNA vaccine encoding the H and N
genes from the attenuated Onderstepoort strain was
investigated by challenge inoculation with the same wild-
type CDV used to create the wild-type DNA vaccine.
The DK91 wild-type CDV strain induces massive lym-
phocyte-associated viremia, lymphopenia and multisystemic
infection in mink [46, 47]. Viremia and lymphopenia are
characteristic for virulent CDV infections in its highly
susceptible natural hosts [44, 47–49]. Long-term protective
immunity was investigated here, as the challenge inocula-
tion was performed 28 weeks after the last immunization
with the DNA vaccines.
Materials and methods
Experimental animals
A total of twenty CDV-seronegative female wild-type mink
(Mustela vison), 10-12 months of age, were purchased from
Østergård Farm (Roskilde, Denmark). The mink had no
records of Aleutian mink disease virus or mink enteritis
virus. Experimental procedures were in accordance with
the requirements of the Danish Animal Care and Ethics
Committee.
Viruses
The wild-type CDV strain DK91B (in short, DK91) was
derived from a dog with acute fatal distemper during an
epidemic in Denmark in 1991 [5]. This wild-type isolate
was propagated by passage of organ homogenates three
times in mink before use in the present study as challenge
inoculum. Spleen homogenates of 10 % or 20 % (w/v) were
prepared in RPMI1640, cleared by centrifugation at 1500 9
g for 10 minutes and frozen in aliquots at -80 C. The
Danish wild-type isolates DK91 and DK91C (from another
acute fatal clinical case from the 1991 epidemic in Den-
mark) were used to produce the wild-type DNA vaccine [5,
50]. In a similar way, CDV-negative spleen homogenates
were prepared from uninfected animals. The Onderstepoort
strain of CDV was used for virus neutralization (VN) test.
Preparation of DNA vaccines
cDNAs encoding CDV DK91 H, N, and F proteins were
subcloned into the eukaryotic expression plasmid vector
pVR1012 (Vical, San Diego, CA, USA), which contains the
cytomegalovirus (CMV) promoter [51]. To facilitate mak-
ing these constructs, site-directed mutagenesis was used to
introduce SalI sites at the 5’ ends and BglII at the 3’ ends of
the H and F cDNAs, and SalI sites at the 5’ ends and XbalI
sites at the 3’ ends of N cDNA. The resulting plasmids were
named pVRCDV-H (1890 bp), pVRCDV-N (1615 bp) and
pVRCDV-F (2204 bp). The inserts were sequenced using
an ABI Prism BigDye Terminator Cycle Sequencing Ready
Reaction Kit (Perkin Elmer) and analyzed in a Prism 310
Genetic Analyzer (Applied Biosystems). For confirmation
of expression, pVRCDV-H, pVRCDV-N and pVRCDV-F
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were introduced by transfection into Vero cells (SuperFect
Transfection Reagent, QIAGEN). Expression of the corre-
sponding CDV proteins was confirmed by using an immu-
nofluorescence assay as described previously [25].
The plasmids pCDV-H and pCDV-N consisted of the
expression plasmid vector pVIJ (p) [52] containing the
insert of the H gene (1815 bp) or the N gene (1573 bp) of
the CDV Onderstepoort strain [44, 46, 53]. The expression
from pCDV-H and pCDV-N has been described and con-
firmed previously [44, 53]. The plasmids were purified
using an EndoFree Plasmid Giga Kit according to the
supplier’s protocol (QIAGEN) with a few modifications
[44, 53]. Purified DNA plasmids were dissolved in phos-
phate-buffered saline to a final concentration of 1 lg/ll.
Administration of DNA vaccines
Immunizations were carried out under anaesthesia with
ketamine hydrochloride (15 mg/kg) and xylazine hydro-
chloride (1 mg/kg) (Ketaminol Vet. and Narcoxyl Vet.,
Intervet, Denmark), which were administered intramuscu-
larly. The vaccine dose was 800 lg of each plasmid. One
third of the dose was administered intradermally, and the
rest, intramuscularly as described previously [44]. Four
mink received the pCDV-H and pCDV-N plasmids (Fig. 1).
Four received a mixture of pVRCDV-H and pVRCDV-N
plasmids, and four received a mixture of pVRCDV-H,
pVRCDV-N and pVRCDV-F plasmids. Two were given the
empty plasmid vector pVR1012 (pVR), and two did not
receive any plasmid (non-vaccinated). The mink were
vaccinated four times at three-week intervals (Fig. 1).
Experimental infection
Challenge inoculation was performed 28 weeks after the
last immunization. Fourteen mink were inoculated with
1.6 9 105 TCID50 per ml of the DK91 wild-type CDV
strain homogenate, and three control animals were inocu-
lated with non-infectious spleen homogenate (Fig. 1).
Under anaesthesia, 1 ml of the homogenate suspension
10 % (w/v) was dripped into each conjunctiva and nostril
and 4 ml of the 20 % (w/v) homogenate was injected
intraperitoneally. Two days later, the animals were given a
second dose of 1 ml of the 10 % spleen homogenate in the
conjunctiva and nostrils. They were then examined daily
for clinical signs of disease throughout the challenge per-
iod, and finally, eight weeks after challenge, they were
anesthetized and then euthanized with barbiturate.
Mink specimens
Blood samples for serum collection and flow cytometric
analysis were drawn by puncture of the vena cephalica
accessoria [54]. Tissues samples were transported on dry
ice and stored at -80 C until two-step RT-PCR were
performed.
Virus neutralization (VN) test
VN antibody determinations were performed in Vero cell
cultures using the TCID50 format microtiter assay and the
Vero-cell-adapted Onderstepoort strain as described pre-
viously [46]. The titers were calculated by the Reed and
Munch method [43].
Two-step RT-PCR assay
Total RNA preparations were isolated using RNA Now
(Ozyme, Biogentex, St Quentin Yvelines, Frances) from
80-100 mg homogenised tissues (brain tissue was taken
from the cranial and caudal part of cerebrum and
cerebellum, mesenteric lymph node, spleen and lung). Two-
step RT-PCR reactions were performed as described previ-
ously [46]. Briefly, cDNA was synthesised from 1 lg of
total RNA using reverse transcriptase and random priming
with hexamers (Advantage RT-for-PCR Kit, Clontech,
Paulo Alto, CA, USA). PCR was performed with the ‘‘uni-
versal’’ primer pair against the phosphoprotein gene first
described by Barrett et al. [55]. As a control for the RNA
extraction, primers for cellular glyceraldehyde-3-phosphate
Vac.  Vac.   Vac.  Vac. Challenge End of exp. 
-37 -34 -31 -28 0 8 weeks
Vaccine Challenge No. of mink 
pCDV-H/-N              
pVRCDV-H/-N       
pVRCDV-H/-N/-F
pVR/non-vaccinated
Control
+
+
+
+
-
n = 4(3)*
n = 4
n = 4(3)*
n = 4
n = 3
Fig. 1 Four mink were vaccinated with a mixture of plasmid vectors
pVIJ (p) expressing the hemagglutinin (H) and nucleoprotein
(N) proteins of the Onderstepoort strain of CDV (pCDV-H/-N).
Eight were vaccinated with plasmid vectors pVR1012 (pVR)
expressing H, N proteins and with or without fusion (F) protein of
the wild-type CDV strain DK91 (pVRCDV-H/-N/-F or pVRCDV-H/-
N). *One mink in the pVRCDV-H/ -N/ -F group and one in the
pCDV-H/ -N group died unexplainably just before the last vaccination
and around five months later, respectively, which reduced the number
of animals to three in each of those groups. Two animals received
empty pVR, and two were left unvaccinated (pVR/non-vaccinated).
The animals were vaccinated four times at three-week intervals and
challenged (day 0 and 2) with the wild-type strain DK91 28 weeks
after the last vaccination. Three mink were included as uninfected
controls
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dehydrogenase were used. The limit of detection of this
assay was 0.03 TCID50 in 1 lg of total RNA [46].
Flow cytometric analysis of peripheral blood
leukocytes
Flow cytometric analysis was carried out on a FACS Cali-
bur flow cytometer (Becton Dickinson, CA, USA) as
described previously [46]. In a forward-scatter-versus-side-
scatter diagram, populations of lymphocytes, monocytes
and granulocytes were gated and quantified (2 9 103
peripheral blood leukocytes were collected). The absolute
leukocyte counts were performed using TruCount quanti-
fication beads (Becton Dickinson) [56]. Within the lym-
phocyte/monocyte gates, 2 9 104 cells were collected for
single-cell cytokine production. An additional 1 9 104 cells
were collected for detection of intracellular CDV-N anti-
gen. The percentages of cytokine-positive cells were
calculated after subtraction of positive signals from isotype-
matched immunoglobulin control preparations. A cross-
reacting monoclonal antibody to bovine interferon gamma
(IFN-c) (catalogue no. MCA 1783, Serotec, Oxford, United
Kingdom) was used [57]. A monoclonal antibody against
the CDV-N protein was used for viral antigen detection
[43]. A rabbit antibody to mouse IgG F(ab0)2 fragments
conjugated to fluorescein isothiocyanate (code no. F0313,
DakoCytomation) was used as secondary antibody. For
statistical evaluations, Student0s t-test was used. All P-values
were two-tailed and were considered statistically significant
when the associated probability was less than 0.05.
Excluded animals
One control mink exhibited extraordinarily low lympho-
cyte counts on the day of inoculation with non-infectious
organ homogenate. The reason for the low lymphocyte
count remained unknown, and the animal was excluded
from the trial. Another mink that had received empty
plasmid (pVR) had a high lymphocyte count on the day of
challenge inoculation and was also excluded.
Results
Virus-neutralizing (VN) antibody responses after DNA
immunization
Mink were immunized four times with plasmids encoding
the CDV genes of the Onderstepoort strain (pCDV-H/ -N)
or with the plasmids encoding CDV genes of the wild-type
DK91 strain (pVRCDV-H/ -N/ -F) as summarized in
Fig. 1. Already after two immunizations, all animals vac-
cinated with the pCDV-H and -N had medium levels of
serum VN antibodies (average titer: 1.9 log10; Fig. 2). In
all DNA-immunized animals, VN antibodies were mea-
sured six weeks after the last immunization, corresponding
to 22 weeks before challenge (-22w in Fig. 2). The VN
antibody titers remained constant without any significant
variations until challenge with the wild-type CDV strain
DK91. The control animals did not develop any detectable
serum VN antibodies during the experimental period
(Fig. 2).
Long-term protective effects of DNA immunization
in mink
Mink were challenged intraperitoneally and on the con-
junctival and nasal mucosa 28 weeks after the last immu-
nization on days 0 and 2 (Fig. 1). The wild-type CDV
strain DK91 caused a mild virulent infection. The animals
in the pVR/non-vaccinated group became lymphopenic
(defined in the legend to Table 1) and viremic (defined here
as positive for cell-associated CDV-N antigen) during the
first weeks after challenge (Figs. 3, 4; Table 1). Sub-
sequent multisystemic infection developed with the pres-
ence of CDV RNA in the lymphoid system (lymph node
and spleen), lung, cerebrum and cerebellum (Table 1).
Thus, DNA immunization of mink had a long-term pro-
tective effect against lymphopenia, viremia and multisys-
temic infection.
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Fig. 2 CDV-specific virus-neutralizing (VN) antibody response
induced by DNA vaccination and after challenge (arrows) with the
DK91 wild-type strain. Blood samples from vaccinated mink (pCDV-
H/ -N: n = 3; pVRCDV-H/ -N: n = 4; pVRCDV-H/ -N/ -F; n = 3),
pVR/non-vaccinated mink (n = 4) and uninfected controls (n = 3)
were collected on the indicated days (d) and weeks (w). The
horizontal dotted line indicate log10 = 2, which equals a neutralizing
titer of 100. The values shown are geometric means ± standard
deviation. The x-axis is not drawn to scale
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Humoral and cellular immune responses after challenge
with wild-type CDV
To evaluate the humoral and cellular immune responses
after challenge, we measured the titer of VN antibodies and
the percentages of IFN-c-producing lymphocytes in the
peripheral blood. The results showed that all of the DNA-
vaccinated animals exhibited a memory VN antibody
response that was already present five days after challenge
(between 1.8- and 2.0-fold increase; Fig. 2). The VN
antibody titers remained above 100 until the end of the
experiment (Fig. 2). Titers above 100 are considered
indicative of protection [49, 58]. Serum VN antibodies in
pVR/non-vaccinated mink were not detectable until two
weeks after challenge, and the average serum VN antibody
titers remained below or at 100 (Fig. 2).
The DNA vaccines were also found to prime the cell-
mediated memory responses, as an early increase in the
number of IFN-c-producing lymphocytes was measured by
flow cytometry (Fig. 5). Interestingly, the early response of
IFN-c-producing lymphocytes found in DNA-vaccinated
animals (Fig. 5a, b; Table 1) was statistically significant
when compared to the pVR/non-vaccinated group (Fig. 5c
and Table 1). In all DNA-vaccinated animals, we detected
an average of 10 % or more IFN-c-producing lymphocytes
on days 6 and 9 after challenge, while less than 3 % IFN-c
producing lymphocytes were found in the pVR/non-vac-
cinated group (Fig. 5 and Table 1). In the pVR-/non-vac-
cinated animals, levels of IFN-c producing lymphocytes
comparable to the ones found in the immunized animals
appeared much later, on days 21 and 28 after challenge
(Fig. 5c and Table 1). Less than 1 % IFN-c-producing
lymphocytes were found in the pVR/non-vaccinated mink
on day 6 after challenge, at the time when the animals were
lymphopenic and viremic. Uninfected control animals were
included to estimate the background level of IFN-c-pro-
ducing lymphocytes. The average background level was
4.0 % to 9.5 % IFN-c-producing lymphocytes throughout
the experimental period (Fig. 5d and Table 1).
Discussion
The aim of the present study was to investigate the immu-
nogenic and protective effect of DNA vaccines based on
different CDV strains against canine distemper in a natural
host. CDV strains isolated from vaccinated dogs with CDV-
related disease have been found to be distinguishable from
Table 1 Long-term protective capacity of the DNA vaccines against CDV
Data are expressed as number of animals testing positive/number tested. Box symbols are explained below. ‘‘–’’, not tested
The mink were challenge 28 weeks after the last immunization and euthanized 8 weeks after challenge with the wild-type DK91 strain. Overt
clinical signs were not observed
a Lymphocytes were quantitated by flow cytometry at days 0, 6 and 9 and weeks 2, 3, 4 and 8 after CDV challenge. Each box represents the
average counts for the group of mink. Grey boxes indicate a[2.2-fold decrease in lymphocyte count when compared to the pre-inoculation counts
(day 0). White boxes represent a B2.2-fold decrease. *One mink vaccinated with pVRCDV-H, -N, -F had transient lymphopenia similar to that
observed in the pVR/non-vaccinated group
b The presence of viral N-antigen in the peripheral blood lymphocytes was analyzed by flow cytometry at days 0, 6 and 9 and weeks 2, 3 and 4
after challenge. Black boxes indicate C20 % positive lymphocytes, grey boxes indicate[5 % positive lymphocytes, striped boxes indicate B5 %
positive lymphocytes, and white boxes indicate that viremia was not detected (defined as less than 3 % positive lymphocytes). Each box
represents individual animals
c The presence of viral RNA was tested in various tissues post-mortem by fragment amplification of CDV phosphoprotein RNA in a two-step RT-
PCR
d Percentage of IFN-c-producing lymphocytes at days 0, 6 and 9 and weeks 2, 3 and 4 after challenge. Black boxes indicate C10 % IFN-c-
positive lymphocytes, grey boxes indicate\10 % IFN-c-positive lymphocytes, and white boxes indicate\1 % IFN-c-positive lymphocytes. Each
box represents the average percentage for each group of animals
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the currently used vaccine strains [4–6, 8, 11, 12, 14, 24].
The heterogeneity found among CDV vaccine strains and
wild-type CDV strains have been speculated to be respon-
sible for the incomplete protection of the vaccinated ani-
mals [5, 19, 59].
To assess whether a wild-type DNA vaccine (pVRCDV-
H/ -N/ -F) is more efficacious against wild-type CDV than
a DNA vaccine based on an attenuated strain (pCDV-H/
-N), the humoral and cellular responses were evaluated in
mink. We found that both DNA vaccines were able to
prime immunological memory responses. Even though
the animals vaccinated with the wild-type plasmids
(pVRCDV-H/-N/-F) did not produce an antibody response
above 100 prior to challenge, all of the immunized animals,
with a single exception, were solidly protected against
lymphocyte-associated viremia, multisystemic infection
and lymphopenia. One mink that was vaccinated with
pVRCDV-H/ -N/ -F developed transient lymphopenia.
Importantly, the vaccine regimens tested in the present
study induced a comparable protective immunity measured
as VN antibodies and IFN-producing lymphocytes against
wild-type CDV. It can still not be ruled out that the
sequence variations between the H genes of vaccine and
circulating wild-type strains can contribute to inadequate
immunity in some vaccinated animals.
Our study indicates that both VN antibodies and cell-
mediated memory responses contribute to protection
against CDV. The relative contribution of VN antibodies
and cell-mediated memory responses to protection remains
unclear. However, to achieve solid disease protection
against CDV and MeV, both cell-mediated and VN anti-
body responses must be induced by the vaccines [35, 36,
38, 53]. An advantage of the DNA vaccines is that there is
no risk of vaccine-induced disease from residual virulence,
which must be considered in the case of attenuated live
vaccines, as illustrated by the formerly used vaccine based
on the Rockborn strain [31]. The Rockborn vaccine was
used globally from 1962 to the mid-1990s, when it was
withdrawn as a consequence of several reported suspected
cases of severe vaccine-induced disease (e.g., post-vaccinal
encephalitis) in dogs who had received the less-attenuated
vaccine [31].
In the current study, 10- to 12-month-old mink were
immunized four times with different combinations of plas-
mids encoding the H, N and F genes from CDV. The DNA
vaccines were administered by the intradermal and intra-
muscular routes, as this combination had previously been
found to induce higher levels of serum antibodies than the
intramuscular route alone [44, 46]. By combined intrader-
mal and intramuscular injections, both Langerhans cells and
myocytes can be primed. Furthermore, this allows a suffi-
cient volume of plasmids to be injected, since only a rela-
tively small volume of DNA vaccine can be administered
b c
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Fig. 3 (a) Lymphocyte levels in vaccinated mink (pCDV-H/ -N;
n = 3: pVRCDV-H/ -N/ -F; n = 3: pVRCDV-H/ -N; n = 4), pVR/
non-vaccinated mink (n = 3) and uninfected controls (n = 3) were
measured by flow cytometry on the indicated days (d) and weeks (w).
Since the lymphocyte counts varied, the lymphocyte counts from the
individual animals were compared to their pre-inoculated counts on
day 0 as illustrated in Table 1. (b) Forward-scatter-versus-side-scatter
dot plot of the lymphocyte (L), monocyte (M) and granulocyte
(G) populations from a mink with a normal lymphocyte count at day 0
and (c) with a transient drop in the lymphocyte count on day 6 after
challenge
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Fig. 4 CDV-N protein detection by flow cytometry in peripheral
blood lymphocytes of vaccinated (pCDV-H/ -N; n = 3: pVRCDV-H/
-N; n = 4) or pVR/non-vaccinated mink (n = 4) on the indicated days
(d) and weeks (w) after challenge with the DK91 strain. Uninfected
controls were included (n = 3). Viral antigen quantification was
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difference between the percentage of CDV-N-positive lymphocytes
from pCDV-H/-N- and pVRCDV-H/-N-vaccinated mink and those
receiving empty plasmids (pVR) or unvaccinated mink
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intradermally. This study showed a strong antibody-based
memory response in the DNA-vaccinated mink. Already
after two immunizations, all of the animals vaccinated with
the pCDV-H and pCDV-N plasmids had medium levels of
serum VN antibodies. In contrast, animals receiving the
wild-type DNA vaccines had only a limited level of serum
VN antibodies. The nucleotide sequences of the open read-
ing frames (ORF) of the DK91 H, N and F genes are 92.1 %,
93.9 % and 91.3 % identical, respectively, to those of the
corresponding ORFs of the Onderstepoort vaccine strain.
These sequence differences may affect the neutralization
titer obtained, as the Vero-cell-adapted Onderstepoort
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Fig. 5 IFN-c-producing lymphocytes from vaccinated mink with
pCDV-H/ -N (n = 3) (a) or with pVRCDV-H/ -N (n = 4) (b), from
mink receiving empty plasmids (pVR) or non-vaccinated mink
(n = 4) (c), and from uninfected control mink (n = 3) (d) on the
indicated days (d) and weeks (w) after challenge. Corresponding IFN-
c and IgG antibody staining profiles of cells within a combined
lymphocyte/monocyte gate of an individual mink are included. The
lymphocyte/monocyte gates were identical to the one shown in Fig. 3.
The horizontal dotted lines indicate the average background level of
IFN-c-producing lymphocytes estimated from the control mink.
* indicates a significant difference between the percentage of IFN-
c-producing lymphocytes from pCDV-H/-N- and pVRCDV-H/-N-
vaccinated mink and those receiving empty plasmids (pVR) or
unvaccinated mink
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vaccine virus was used in the VN antibody assay [28, 60].
Therefore, in further studies, it would be preferable to test
serum samples for neutralizing activity against the homol-
ogous wild-type virus from which the relevant vaccine is
generated to clarify whether the low antibody levels might
be due to an antigenic difference between the CDV strains.
However, in the present study we were able to shown that
both DNA vaccines induced a solid neutralizing antibody
response in mink after challenge. Moreover, a previous in
vitro study has shown that the sequence difference between
wild-type and vaccine strains did not have any significant
influence on the cross-reactivity of CDV-positive sera in
neutralizing assays [9].
The wild-type DNA plasmids (pVRCDV-H/-N/ -F) were
designed to contain the H, N or F genes (starting 12, 12 and
86 nucleotides upstream of the start codon and ending 55,
31 and 135 nucleotides downstream of the stop codon,
respectively), while only the ORFs of Onderstepoort H and
N were inserted into the plasmids (pCDV-H/ -N). Both
expression plasmids contained the cytomegalovirus (CMV)
promoter. The extra Kozak nucleotides in the pVRCDV-
H/-N/ -F may have an influence on the expression of the
proteins. For DNA vaccines, it is essential to prime anti-
gen-presenting cells to present the antigens on both MHC I
and MHC II to T cells. In addition to the ability of the
plasmids to express the antigen in vivo, other factors such
as post-translational modification can have an influence on
the presentation of the antigen on the antigen-presenting
cells [61].
The F gene was included in the DNA vaccine with the
wild-type strain to assess if it induced a stronger overall
immune response. In the present study, the VN antibody
levels of the two groups of mink receiving pVRCDV-H/ -N
or pVRCDV-H/-N/-F were found to be comparable, without
any significant differences. In future studies, it will be
interesting to evaluate the contribution of F plasmids to the
cell-mediated memory response. In this study, immuniza-
tion with plasmids encoding the H and N genes primed a
cell-mediated memory response, as shown by an early
increase in the percentage of IFN-c-producing lymphocytes.
We observed no overt clinical signs of distemper, which
is in contrast to a previous experiment in 6-month-younger
mink infected with the wild-type CDV strain DK91 [46].
The reason for this lack of clinical symptoms is most likely
the different doses of challenge material used (a tenfold
lower challenge dose was used in the present study),
although the lack of clinical symptoms could also be
attributed to the age of the animals, as young animals are
more susceptible to severe disease, than older ones [58, 62–
65]. However, the extent of lymphopenia and lymphocyte-
associated CDV N antigen found in the pVR/non-vacci-
nated group corresponds to data obtained in our previous
studies [46, 47]. Our finding of a protective immune
response in DNA-vaccinated mink against challenge with a
virulent strain of CDV encourages further studies. It is
important to test the DNA vaccines further against a
challenge that induces overt clinical signs in unvaccinated
animals.
In summary, these results demonstrated induction of VN
antibody and cell-mediated (IFN-c) immune responses in
DNA-vaccinated mink compared to pVR/non-vaccinated
mink after challenge with wild-type CDV. An immuno-
logical memory response was observed in all of the DNA-
immunized animals, and the vaccine-induced immunity
provided long-term protection against CDV challenge. Our
results showed cross-protection between DNA vaccines
based on the vaccine strain against wild-type CDV chal-
lenge. The protective capacity was comparable with that
induced by the wild-type vaccine. However, the heteroge-
neity between the currently circulating wild-type and
vaccine strains must still be considered in future vaccine
strategies against CDV to ensure cross-protection. One
approach to minimize potential vaccine failures due to
genetic and antigenic differences between attenuated
strains used to generate the DNA-vaccines and circulating
virulent strains of CDV is to immunize with DNA vaccines
containing both the H and more-conserved internal anti-
gens. Immunization with the conserved internal antigens N
or matrix protein seems to ensure a broader cross-protec-
tion against influenza viruses, which undergo antigenic
shift and drift [66].
In perspective, the continuous outbreaks of distemper
and the ongoing measles outbreaks in Europe and Africa
illustrate the need for the development of new, improved
vaccines for prophylaxis, and in the case of measles,
eventual eradication [67]. The relatively large amount of
plasmid DNA and multiple injections used in this study to
induce immunity compared to the existing licensed modi-
fied live-virus vaccines must be minimized before the DNA
vaccines can be used commercially. However, we believe
that our finding of a long-term protective effect against
wild-type challenge encourages further studies on DNA
immunization to reduce the dose of DNA and the number
of vaccinations required. One approach to improve the
immune response could include immunostimulatory factors
like cytokines. Co-administration of a DNA vaccine
encoding the MeV H, F and N proteins with an IL-2
molecular adjuvant has been shown to increase the anti-
body response and the cell-mediated immune response and
enhance the level of protection against viremia in newborn
macaques [36].
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